2023
DOI: 10.5603/cj.a2021.0099
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of long-term clinical outcomes among zotarolimus-, everolimus-, and biolimus-eluting stents in acute myocardial infarction patients with renal impairment

Abstract: This article has been peer reviewed and published immediately upon acceptance.It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 48 publications
0
1
0
Order By: Relevance
“…Biolimus is most widely used in BP-DES and PF-DES stents and, unlike other -limus analogues, it was specifically developed for coronary-stent usage [ 87 ]. In a comparison study of various zotarolimus, everolimus and biolimus stents, there were no significant differences in long-term MACE, all-cause mortality, any revascularization, rehospitalization and stent thrombosis [ 88 ]. As previously mentioned, the summary efficacy of a stent is based not only on the drug itself but the entire stent architecture.…”
Section: Polymers and Coatingmentioning
confidence: 99%
“…Biolimus is most widely used in BP-DES and PF-DES stents and, unlike other -limus analogues, it was specifically developed for coronary-stent usage [ 87 ]. In a comparison study of various zotarolimus, everolimus and biolimus stents, there were no significant differences in long-term MACE, all-cause mortality, any revascularization, rehospitalization and stent thrombosis [ 88 ]. As previously mentioned, the summary efficacy of a stent is based not only on the drug itself but the entire stent architecture.…”
Section: Polymers and Coatingmentioning
confidence: 99%